RPG Life Sciences Limited — PPTs, 02-06-2025: Investor Presentation

1. Financial Highlights:

Revenue grew 12% YoY to Rs. 653.4 Cr, with PBT rising 28% YoY and EBITDA margin expanding from 23.3% to 26.4%. ROE improved to 24.3%, ROCE to 32.9%, and EPS hit Rs. 67.5 — nearly 10x FY19 levels. The company remains debt-free with strong cash accruals and invested around Rs. 140 Cr in capex focused on plant modernization and R&D.

2. Strategic Initiatives & Growth Drivers:

Growth is driven by core immunosuppressants and specialty brands, with Naprosyn sales nearing Rs. 76 Cr and a Rs. 100 Cr target. Rheumatology contributes 14% to the specialty portfolio, while new segments like ortho and critical care are being explored. Digital projects aim to boost efficiency and compliance. Focus areas include expanding in new geographies, product launches, and improving manufacturing productivity.

3. Business Developments:

The company holds Rs. 267 Cr in surplus cash earmarked for inorganic growth through targeted acquisitions in select therapies and brands. Product pipeline expansion across multiple segments supports efforts to deepen market presence.

4. Market Position & Competitive Advantage:

RPG Life Sciences leads in immunosuppressants and specialty therapies with three globally compliant manufacturing sites. Legacy and strong ‘textbook’ brands underpin a solid position in chronic and specialty markets, contributing to margin expansion and market cap outperformance.

5. Investor Implications:

Robust financials combined with strategic capex, pipeline growth, and a clean balance sheet offer positive growth potential. Investors should watch execution around M&A and portfolio expansion as key value drivers. Operational improvements and digital transformation support sustained margin gains.